Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation,
Utilising its collaboration with Microsoft and a team of multidisciplinary scientists, the company is poised to disrupt the conventional therapeutic discovery model. The company was co-founded by Dr
The application is currently being evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Mavorixafor would become the first drug for this syndrome in the European
Memantine/donepezil 14-10 mg and 28-10 mg capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. This product, referencing NAMZARIC of AbbVie, has
Nearly $25m of the revenue is anticipated for the products under this contract. A human rabies immune globulin (HRIG), KAMRAB is designed for passive, transient post-exposure prophylaxis (PEP)
Designed to target oxidative stress related to RP, NPI-001 is the company’s investigational candidate. In preclinical studies, the therapy improved glutathione, which is said to be the most
The company has announced that soon, the injection will be available to ophthalmologists and their patients, and ongoing efforts are being made to ensure accessibility via public and
Developed by Fermion, FZ002-037 is an oral somatostatin receptor 4 (SSTR4) agonist. Under the terms of the agreement, Simcere will obtain exclusive rights for developing and commercialising the drug
This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC). With this funding, the company’s total Series A equity value raised to over
The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Axcynsis Therapeutics CEO Dr Zou Bin said:
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.